Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$129.91 USD

129.91
435,180

+3.02 (2.38%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $130.22 +0.31 (0.24%) 5:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Momentum Stocks Worth Investing in via Driehaus Strategy

by Zacks Equity Research

Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.

    Zacks Equity Research

    ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    ICU Medical (ICUI) delivered earnings and revenue surprises of 45.36% and 7.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Zacks Equity Research

      Is ICU Medical (ICUI) Stock Outpacing Its Medical Peers This Year?

      by Zacks Equity Research

      Is ICU Medical, Inc. (ICUI) Outperforming Other Medical Stocks This Year?

        Zacks Equity Research

        Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI

        by Zacks Equity Research

        Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI

          Zacks Equity Research

          Shrug Off Market Volatility With These 5 Low Beta Stocks

          by Zacks Equity Research

          We develop a strategy that clearly shows that less risky stocks have the potential to reward shareholders with impressive returns only when certain parameters are considered.

            Zacks Equity Research

            LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?

            by Zacks Equity Research

            LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.

              Zacks Equity Research

              Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural

              by Zacks Equity Research

              Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural

                Zacks Equity Research

                Rely on Driehaus Strategy and Buy These 5 Momentum Stocks

                by Zacks Equity Research

                Investors with high risk-tolerance can invest in momentum stocks using Driehaus Strategy.

                  Zacks Equity Research

                  Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group

                  by Zacks Equity Research

                  Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group

                    Zacks Equity Research

                    Boost Immunity to Market Volatility With 5 Low-Beta Stocks

                    by Zacks Equity Research

                    We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.

                      Zacks Equity Research

                      ICU Medical (ICUI) Hits a 52-Week-High, Can the Run Continue?

                      by Zacks Equity Research

                      ICU Medical, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for ICUI for clues.

                        Nabaparna Bhattacharya headshot

                        Fresenius Medical (FMS) Q4 Earnings Beat, View Impressive

                        by Nabaparna Bhattacharya

                        Higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care boost Fresenius Medical (FMS) in Q4.

                          Zacks Equity Research

                          Here's Why You Should Invest in Bio-Rad (BIO) Right Now

                          by Zacks Equity Research

                          Positive tidings on the regulatory front and strong fourth-quarter performance boost investors' confidence in Bio-Rad (BIO).

                            Zacks Equity Research

                            Veeva Systems Rides on Strong Q4 & Cloud-Based Applications

                            by Zacks Equity Research

                            Industry expertise and expanding product portfolio in cloud-based solutions to bolster Veeva Systems' (VEEV) prospects.

                              Zacks Equity Research

                              Cerner Collaborates With Salesforce, Focuses on AI Trends

                              by Zacks Equity Research

                              Cerner (CERN) has been in the headlines, courtesy of its consistent efforts to digitize electronic health record systems.

                                Zacks Equity Research

                                Ecolab Gains From Strength in Global Industrial Segment

                                by Zacks Equity Research

                                Ecolab (ECL) witnesses improvement in underlying sales volume and pricing in most business segments.

                                  Zacks Equity Research

                                  Will International Expansion Aid JD.com (JD) Q4 Earnings?

                                  by Zacks Equity Research

                                  Strong growth in e-commerce business and international expansion are likely to drive JD.com's fourth-quarter earnings.

                                    Mark Vickery headshot

                                    MedTech's Long-Term Prospects Outweigh Near-Term Risks

                                    by Mark Vickery

                                    A growing prevalence of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care and the shift of the payment system to a value-based model are among the updates.

                                      Zacks Equity Research

                                      Product Innovation Drives Illumina, Downbeat Margins a Woe

                                      by Zacks Equity Research

                                      Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.

                                        Zacks Equity Research

                                        PRA Health (PRAH) Hits 52-Week High on Multiple Positives

                                        by Zacks Equity Research

                                        PRA Health (PRAH) touches 52-week high on consistent revenue performance and Symphony Health integration.

                                          Zacks Equity Research

                                          Zimmer Biomet Suffers a Dull Knee Business & Supply Delay

                                          by Zacks Equity Research

                                          Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.

                                            Zacks Equity Research

                                            ICU Medical (ICUI) in Focus: Stock Moves 10.2% Higher

                                            by Zacks Equity Research

                                            ICU Medical (ICUI) saw its shares rise over 10% on the day.

                                              Zacks Equity Research

                                              Should You Buy ICU Medical (ICUI) Ahead of Earnings?

                                              by Zacks Equity Research

                                              ICU Medical (ICUI) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                                Zacks Equity Research

                                                4 Medical Device Stocks to Top Q3 Earnings

                                                by Zacks Equity Research

                                                A look at how medical device players are poised for this earnings season.

                                                  Zacks Equity Research

                                                  Pfizer (PFE) Beats on Q3 Earnings, Raises 2017 EPS View

                                                  by Zacks Equity Research

                                                  Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised its adjusted earnings guidance while tightening revenue expectations for 2017.